How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/infection-caused-by-acinetobacter-spp-resistant-to-carbapenem-antimicrobial-drugs.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Infection caused by Acinetobacter spp resistant to carbapenem antimicrobial drugs — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Infection caused by Acinetobacter spp resistant to carbapenem antimicrobial drugs (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Infection caused by Acinetobacter spp resistant to carbapenem antimicrobial drugs, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Recarbrio	RELEBACTAM	Merck & Co.	Renal Dehydropeptidase Inhibitor [EPC]		2019-01-01
Primaxin	IMIPENEM	Merck Sharp & Dohme B.V.	imipenem		1985-01-01
Primaxin	CILASTATIN	Merck & Co.	Renal Dehydropeptidase Inhibitor	Dipeptidase 1	1985-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Merck & Co. · 2 drugs in Infection caused by Acinetobacter spp resistant to carbapenem antimicrobial drugs
Merck Sharp & Dohme B.V. · 1 drug in Infection caused by Acinetobacter spp resistant to carbapenem antimicrobial drugs

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Infection caused by Acinetobacter spp resistant to carbapenem antimicrobial drugs:

Cite this brief

Drug Landscape (2026). Infection caused by Acinetobacter spp resistant to carbapenem antimicrobial drugs — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/infection-caused-by-acinetobacter-spp-resistant-to-carbapenem-antimicrobial-drugs. Accessed 2026-06-10.

Infection caused by Acinetobacter spp resistant to carbapenem antimicrobial drugs full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing